List of bibliographic references indexed by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Number of relevant bibliographic references: 38.
[0-20] [
0 - 20][
0 - 38][
20-37][
20-40]
| Ident. | Authors (with country if any) | Title |
|---|
| 001C97 (2010) |
Marta G. Vu Ckovi [États-Unis] ; Quanzheng Li [États-Unis] ; Beth Fisher [États-Unis] ; Angelo Nacca [États-Unis] ; Richard M. Leahy [États-Unis] ; John P. Walsh [États-Unis] ; Jogesh Mukherjee [États-Unis] ; Celia Williams [États-Unis] ; Michael W. Jakowec [États-Unis] ; Giselle M. Petzinger [États-Unis] | Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: In vivo imaging with [18F]fallypride |
| 002789 (2008) |
Jose L. Lanciego [Espagne] ; Maria C. Rodríguez-Oroz [Espagne] ; Francisco J. Blesa [Espagne] ; Lydia Alvarez-Erviti [Espagne] ; Jorge Guridi [Espagne] ; Pedro Barroso-Chinea [Espagne] ; Yoland Smith [États-Unis] ; Jose A. Obeso [Espagne] | Lesion of the centromedian thalamic nucleus in MPTP‐treated monkeys |
| 003018 (2007) |
Regina Katzenschlager [Royaume-Uni, Autriche] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Kim Stockwell [Royaume-Uni] ; Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Mohammed Zubair [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets |
| 003143 (2006) |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure |
| 003277 (2006) |
Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 003402 (2006) |
Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L‐dopa–induced chorea, but not dystonia, in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 003569 (2006) |
Gloria E. Meredith [États-Unis] ; Un Jung Kang [États-Unis] | Behavioral models of Parkinson's disease in rodents: A new look at an old problem |
| 004038 (2003) |
Michael Orth [Royaume-Uni] ; Sarah J. Tabrizi [Royaume-Uni] | Models of Parkinson's disease |
| 004092 (2003) |
Jay S. Schneider [États-Unis] ; Timothy V. Wade [États-Unis] | Experimental parkinsonism is associated with increased pallidal GAD gene expression and is reversed by site‐directed antisense gene therapy |
| 004280 (2002) |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 004563 (2002) |
Mikko Kuoppam Ki [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Michael Jackson [Royaume-Uni] ; Lance Smith [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa |
| 004737 (2001) |
R. E. Yee [États-Unis] ; I. Irwin [États-Unis] ; C. Milonas [Suède] ; D. B. Stout [États-Unis] ; S-C. Huang [États-Unis] ; K. Shoghi-Jadid [États-Unis] ; N. Satyamurthy [États-Unis] ; L. E. Delanney [États-Unis] ; D. M. Togasaki [États-Unis] ; K. F. Farahani [États-Unis] ; K. Delfani [États-Unis] ; A. M. Janson [Suède] ; M. E. Phelps [États-Unis] ; J. W. Langston [États-Unis] ; J. R. Barrio [États-Unis] | Novel observations with FDOPA‐PET imaging after early nigrostriatal damage |
| 004745 (2001) |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan |
| 004872 (2001) |
Eleni C. Maratos [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Antiparkinsonian activity and dyskinesia risk of ropinirole and L‐DOPA combination therapy in drug naive MPTP‐lesioned common marmosets (Callithrix jacchus) |
| 004931 (2000) |
Imad Ghorayeb [France] ; Pierre O. Fernagut [France] ; Incarnation Aubert [France] ; Erwan Bezard [France] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] ; François Tison [France] | Toward a primate model of l‐dopa‐unresponsive parkinsonism mimicking striatonigral degeneration |
| 004976 (2000) |
Donato A. Di Monte [États-Unis] ; Alison Mccormack [États-Unis, Suède] ; Giselle Petzinger [États-Unis] ; Ann Marie Janson [États-Unis, Suède] ; Maryka Quik [États-Unis] ; William J. Langston [États-Unis] | Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model |
| 004E08 (1999) |
Edna Grünblatt [Israël] ; Silvia Mandel [Israël] ; Tamara Berkuzki [Israël] ; M. B. H. Youdim [Israël] | Apomorphine protects against MPTP‐induced neurotoxicity in mice |
| 005017 (1998) |
Jay S. Schneider [États-Unis] ; Anne Pope-Coleman [États-Unis] ; Maria Van Velson [États-Unis] ; Frederique Menzaghi [États-Unis] ; G. Kenneth Lloyd [États-Unis] | Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys |
| 005034 (1998) |
Ronald K. B. Pearce [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jenner [Royaume-Uni] ; C. David Marsden [Royaume-Uni] | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset |
| 005079 (1998) |
Pierre J. Blanchet [États-Unis] ; Spyridon Konitsiotis [États-Unis] ; Thomas N. Chase [États-Unis] | Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys |
| 005238 (1997) |
Lise Rioux [États-Unis] ; Paul A. Frohna [États-Unis] ; Joyce [États-Unis] ; Jay S. Schneider [États-Unis] | The effects of chronic levodopa treatment on pre‐ and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i \
-Sk "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= indexItem
|index= KwdEn.i
|clé= 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
